- Serán Bioscience has announced a growth investment led by Biospring Partners, existing investors, and the company’s executive leadership to support its expansion from clinical to commercial services.
- The CDMO plans to complete a new multi-suite commercial manufacturing facility in the third quarter of 2027, adding particle engineering and finished dose capabilities.
Serán Bioscience, a contract development and manufacturing organization (CDMO) serving pharmaceutical and biotechnology companies, has announced a growth investment to accelerate its expansion across clinical and commercial services. The investment will support expanded capabilities in particle engineering and commercial-scale manufacturing in response to client demand.
The company plans to construct a new commercial facility targeted for completion in the third quarter of 2027. The multi-suite facility will support OEB4 manufacturing for oral, pulmonary, and other delivery modalities. Its particle engineering capabilities will include spray drying and nano-milling.
The facility will also provide finished dose manufacturing capabilities, including granulation, tableting, coating, encapsulation, and specialized dry powder filling for inhalation products across immediate- and modified-release profiles. The expansion will be integrated with Serán’s recently completed adjacent packaging and logistics facility, which provides packaging, labeling, unit-level serialization, and global cold-chain distribution.
“This investment is a significant milestone in Serán’s evolution as we rapidly scale our clinical manufacturing operations to support launches of new medicines, as well as serve new clients seeking a state-of-the-art commercial manufacturing partner.”
Dan Smithey, Co-Founder and CEO of Serán
Serán currently has more than 200 team members and plans to hire up to 150 additional employees as the commercial expansion progresses.
